期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型口服抗凝药物相关性出血的处理策略现状 被引量：3

原文传递
导出
摘要 新型口服抗凝药物（NOACs）包括直接凝血酶抑制剂（达比加群）和直接Xa因子抑制剂（阿哌沙班、利伐沙班），因其具有起效快、半衰期短、药物间相互作用少、药代动力学确切、个体差异小等优点而受到广泛关注。
作者 郑晶 夏云龙 杨延宗
机构地区 大连医科大学附属第一医院心内科
出处 《中华临床医师杂志（电子版）》 CAS 2013年第17期144-145,共2页 Chinese Journal of Clinicians(Electronic Edition)
关键词 口服抗凝药物 药物相关性 直接凝血酶抑制剂 XA因子抑制剂 药物间相互作用 出血 药代动力学 利伐沙班
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献20

  • 1Sebastian H?rtter,Regina Sennewald,Gerhard Nehmiz,Paul Reilly.Oral bioavailability of dabigatran etexilate ( P radaxa<sup>?</sup>) after co‐medication with verapamil in healthy subjects[J].Br J Clin Pharmacol.2013(4)
  • 2Greg C. Flaker,John W. Eikelboom,Olga Shestakovska,Stuart J. Connolly,Scott Kaatz,Andrzej Budaj,Steen Husted,Salim Yusuf,Gregory Y. H. Lip,Robert G. Hart.Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial[J].Stroke.2012(12)
  • 3Matthew R Wanek,Edward T Horn,Subbarao Elapavaluru,Samuel C Baroody,George Sokos.Safe Use of Hemodialysis for Dabigatran Removal Before Cardiac Surgery[J].Annals of Pharmacotherapy.2012(9)
  • 4Renato D Lopes,Sana M Al-Khatib,Lars Wallentin,Hongqiu Yang,Jack Ansell,M Cecilia Bahit,Raffaele De Caterina,Paul Dorian,J Donald Easton,Cetin Erol,Justin A Ezekowitz,Bernard J Gersh,Christopher B Granger,Stefan H Hohnloser,John Horowitz,Elaine M Hylek,John JV McMurray,Puneet Mohan,Dragos Vinereanu,John H Alexander.Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial[J].The Lancet.2012(9855)
  • 5Shawn E. Fellows,Jamie M. Rosini,James A. Curtis,Emilio G. Volz.Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency[J].Journal of Emergency Medicine.2012
  • 6Don N. Chang,William E. Dager,Andrew I. Chin.Removal of Dabigatran by Hemodialysis[J].American Journal of Kidney Diseases.2012
  • 7Rajesh Krishna,Daria Stypinski,Melissa Ali,Amit Garg,Josee Cote,Andrea Maes,Bruce DeGroot,Yang Liu,Susie Li,Sandra M. Connolly,John A. Wagner,S. Aubrey Stoch.Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects[J].British Journal of Clinical Pharmacology.2012(1)
  • 8Joseph A.Grillo,PingZhao,JulieBullock,Brian P.Booth,MinLu,KathyRobie‐Suh,Eva GilBerglund,K. SandyPang,AtiqurRahman,LeiZhang,Lawrence J.Lesko,Shiew‐MeiHuang.Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice[J].Biopharm Drug Dispos.2012(2)
  • 9Masaki Watanabe,Fazeel M. Siddiqui,Adnan I. Qureshi.Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment[J].Neurocritical Care.2012(1)
  • 10Wei Zhou,S?nke Schwarting,Sergio Illanes,Arthur Liesz,Moritz Middelhoff,Markus Zorn,Martin Bendszus,Sabine Heiland,Joanne van Ryn,Roland Veltkamp.Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran[J].Stroke.2011(12)

同被引文献43

引证文献3

二级引证文献27

中华临床医师杂志（电子版）
2013年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部